MASI Quote, Financials, Valuation and Earnings

AngioDynamics has a net margin of 1.94% compared to Masimo's net margin of -18.95%. Masimo's return on equity of 5.75% beat AngioDynamics's return on equity of -56.49%.

Masimo has a consensus price target of $172.77, signalling upside risk potential of 3.14%. On the other hand AngioDynamics has an analysts' consensus of -- which suggests that it could grow by 46.73%. Given that AngioDynamics has higher upside potential than Masimo, analysts believe AngioDynamics is more attractive than Masimo.

Masimo has a beta of 1.010, which suggesting that the stock is 1.04% more volatile than S&P 500. In comparison AngioDynamics has a beta of 0.677, suggesting its less volatile than the S&P 500 by 32.305%.

Masimo has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AngioDynamics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Masimo pays -- of its earnings as a dividend. AngioDynamics pays out -- of its earnings as a dividend.

Masimo quarterly revenues are $504.6M, which are larger than AngioDynamics quarterly revenues of $71M. Masimo's net income of $9.8M is higher than AngioDynamics's net income of -$13.4M. Notably, Masimo's price-to-earnings ratio is 115.52x while AngioDynamics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Masimo is 4.46x versus 1.22x for AngioDynamics. Usually stocks with elevated PS ratios are considered overvalued.

Boston Scientific has a net margin of 1.94% compared to Masimo's net margin of 11.12%. Masimo's return on equity of 5.75% beat Boston Scientific's return on equity of 8.91%.

Masimo has a consensus price target of $172.77, signalling upside risk potential of 3.14%. On the other hand Boston Scientific has an analysts' consensus of $99.14 which suggests that it could grow by 10.33%. Given that Boston Scientific has higher upside potential than Masimo, analysts believe Boston Scientific is more attractive than Masimo.

Masimo has a beta of 1.010, which suggesting that the stock is 1.04% more volatile than S&P 500. In comparison Boston Scientific has a beta of 0.802, suggesting its less volatile than the S&P 500 by 19.799%.

Masimo has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Masimo pays -- of its earnings as a dividend. Boston Scientific pays out 1.76% of its earnings as a dividend. Boston Scientific's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Masimo quarterly revenues are $504.6M, which are smaller than Boston Scientific quarterly revenues of $4.2B. Masimo's net income of $9.8M is lower than Boston Scientific's net income of $468M. Notably, Masimo's price-to-earnings ratio is 115.52x while Boston Scientific's PE ratio is 74.26x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Masimo is 4.46x versus 8.37x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.

Globus Medical has a net margin of 1.94% compared to Masimo's net margin of 8.28%. Masimo's return on equity of 5.75% beat Globus Medical's return on equity of 2.27%.

Masimo has a consensus price target of $172.77, signalling upside risk potential of 3.14%. On the other hand Globus Medical has an analysts' consensus of $94.23 which suggests that it could grow by 13.39%. Given that Globus Medical has higher upside potential than Masimo, analysts believe Globus Medical is more attractive than Masimo.

Masimo has a beta of 1.010, which suggesting that the stock is 1.04% more volatile than S&P 500. In comparison Globus Medical has a beta of 1.190, suggesting its more volatile than the S&P 500 by 19.035%.

Masimo has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Globus Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Masimo pays -- of its earnings as a dividend. Globus Medical pays out -- of its earnings as a dividend.

Masimo quarterly revenues are $504.6M, which are smaller than Globus Medical quarterly revenues of $625.7M. Masimo's net income of $9.8M is lower than Globus Medical's net income of $51.8M. Notably, Masimo's price-to-earnings ratio is 115.52x while Globus Medical's PE ratio is 124.03x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Masimo is 4.46x versus 4.60x for Globus Medical. Usually stocks with elevated PS ratios are considered overvalued.

Tandem Diabetes Care has a net margin of 1.94% compared to Masimo's net margin of -9.53%. Masimo's return on equity of 5.75% beat Tandem Diabetes Care's return on equity of -47.23%.

Masimo has a consensus price target of $172.77, signalling upside risk potential of 3.14%. On the other hand Tandem Diabetes Care has an analysts' consensus of -- which suggests that it could grow by 39.31%. Given that Tandem Diabetes Care has higher upside potential than Masimo, analysts believe Tandem Diabetes Care is more attractive than Masimo.

Masimo has a beta of 1.010, which suggesting that the stock is 1.04% more volatile than S&P 500. In comparison Tandem Diabetes Care has a beta of 1.324, suggesting its more volatile than the S&P 500 by 32.425%.

Masimo has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tandem Diabetes Care offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Masimo pays -- of its earnings as a dividend. Tandem Diabetes Care pays out -- of its earnings as a dividend.

Masimo quarterly revenues are $504.6M, which are larger than Tandem Diabetes Care quarterly revenues of $244M. Masimo's net income of $9.8M is higher than Tandem Diabetes Care's net income of -$23.3M. Notably, Masimo's price-to-earnings ratio is 115.52x while Tandem Diabetes Care's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Masimo is 4.46x versus 2.80x for Tandem Diabetes Care. Usually stocks with elevated PS ratios are considered overvalued.